The additional follow-up data on the first cohort in the in Retinitis Pigmentosa (RP) Phase I/II trial confirms a sustained and clinically meaningful improvement in visual acuity (an average 23-point improvement on the ETDRS chart vs. an average 5-point improvement in placebo-treated eyes). In our view, the emerging results from the Phase I/II trial are highly encouraging and indicative of a clinically meaningful effect. We note that ReNeuron’s hRPC programme in RP benefits from both Orphan desi ....
26 Apr 2019
Further data from RP trial: improvement in visual acuity sustained
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Further data from RP trial: improvement in visual acuity sustained
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
26 Apr 2019 -
Author:
Dr Jens Lindqvist -
Pages:
3
The additional follow-up data on the first cohort in the in Retinitis Pigmentosa (RP) Phase I/II trial confirms a sustained and clinically meaningful improvement in visual acuity (an average 23-point improvement on the ETDRS chart vs. an average 5-point improvement in placebo-treated eyes). In our view, the emerging results from the Phase I/II trial are highly encouraging and indicative of a clinically meaningful effect. We note that ReNeuron’s hRPC programme in RP benefits from both Orphan desi ....